Treatment With the Dipeptidyl Peptidase-4 Inhibitor Linagliptin or Placebo Followed by Glimepiride in Patients With Type 2 Diabetes With Moderate to Severe Renal Impairment: A 52-Week, Randomized, Double-Blind Clinical Trial

Laakso Markku; Rosenstock Julio; Groop Per-Henrik; Barnett Anthony H.; Gallwitz Baptist; Hehnke Uwe; Tamminen Ilkka; Patel Sanjay; von Eynatten Maximilian; Woerle Hans-Juergen

首页> 外文期刊>Diabetes care >Treatment With the Dipeptidyl Peptidase-4 Inhibitor Linagliptin or Placebo Followed by Glimepiride in Patients With Type 2 Diabetes With Moderate to Severe Renal Impairment: A 52-Week, Randomized, Double-Blind Clinical Trial

【24h】

Treatment With the Dipeptidyl Peptidase-4 Inhibitor Linagliptin or Placebo Followed by Glimepiride in Patients With Type 2 Diabetes With Moderate to Severe Renal Impairment: A 52-Week, Randomized, Double-Blind Clinical Trial

机译：接受中度至重度肾功能不全的2型糖尿病患者用Depteptidyl Peptidase-4抑制剂Linagliptin或安慰剂联合格列美脲治疗：一项52周，随机，双盲临床试验

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Diabetes care》 |2015年第2期|共3页
作者
Laakso Markku; Rosenstock Julio; Groop Per-Henrik; Barnett Anthony H.; Gallwitz Baptist; Hehnke Uwe; Tamminen Ilkka; Patel Sanjay; von Eynatten Maximilian; Woerle Hans-Juergen;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类内分泌腺疾病及代谢病;
关键词

相似文献

外文文献
中文文献
专利

1. Treatment With the Dipeptidyl Peptidase-4 Inhibitor Linagliptin or Placebo Followed by Glimepiride in Patients With Type 2 Diabetes With Moderate to Severe Renal Impairment: A 52-Week, Randomized, Double-Blind Clinical Trial [J] . Laakso Markku, Rosenstock Julio, Groop Per-Henrik, Diabetes care . 2015,第2期

机译：接受中度至重度肾功能不全的2型糖尿病患者用Depteptidyl Peptidase-4抑制剂Linagliptin或安慰剂联合格列美脲治疗：一项52周，随机，双盲临床试验
2. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients. [J] . Horie Y, Kanada S, Watada H, Clinical therapeutics . 2011,第7期

机译：二肽基肽酶-4抑制剂利格列汀的药代动力学，药效学和耐受性概况：在日本2型糖尿病患者中进行的为期4周的多中心，随机，双盲，安慰剂对照IIa期研究。
3. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: A randomised controlled 52-week efficacy and safety study [J] . NowickiM., RychlikI., HallerH., International journal of clinical practice . 2011,第12期

机译：二肽基肽酶-4抑制剂沙格列汀对2型糖尿病和肾功能不全患者的长期治疗：随机对照52周疗效和安全性研究
4. Fragment-Based Drug Design to Discover Novel Inhibitor of Dipeptidyl Peptidase-4 (DPP-4) as a Potential Drug for Type 2 Diabetes Therapy [C] . Eka Gunarti Ningsih, Muhammad Fauzi Hidayat, Usman Sumo Friend Tambunan International work-conference on bioinformatics and biomedical engineering . 2019

机译：基于片段的药物设计，发现二肽基肽酶-4（DPP-4）的新型抑制剂作为2型糖尿病治疗的潜在药物
5. A Randomized, Double-blind, Placebo-controlled Clinical Trial Evaluating the Effect of Infliximab on General Cognition in a Population of Depressed Individuals with Bipolar Disorder Type I/II [D] . Pan, Zihang. 2018

机译：一项随机，双盲，安慰剂对照的临床试验，评估英夫利昔单抗对I / II型双相情感障碍抑郁症患者总体认知的影响
6. Effect of linagliptin a dipeptidyl peptidase-4 inhibitor compared with the sulfonylurea glimepiride on cardiovascular outcomes in Asians with type 2 diabetes: subgroup analysis of the randomized CAROLINA® trial [O] . Takashi Kadowaki, Guang Wang, Julio Rosenstock, 2021

机译：二肽肽肽酶-4抑制剂Linaglittin的影响与亚磺酰脲胶质脂质在亚洲患有2型糖尿病的心血管结果上的影响：随机Carolina®试验的亚组分析
7. Treatment With the Dipeptidyl Peptidase-4 Inhibitor Linagliptin or Placebo Followed by Glimepiride in Patients With Type 2 Diabetes With Moderate to Severe Renal Impairment: A 52-Week, Randomized, Double-Blind Clinical Trial: Figure 1 [O] . Markku Laakso, Julio Rosenstock, Per-Henrik Groop, 2015

机译：用二肽肽酶-4抑制剂Linagliptin或安慰剂治疗，然后是2型糖尿病患者的肾小序，中度至重度肾损伤：A 52周，随机，双盲临床试验：图1

Treatment With the Dipeptidyl Peptidase-4 Inhibitor Linagliptin or Placebo Followed by Glimepiride in Patients With Type 2 Diabetes With Moderate to Severe Renal Impairment: A 52-Week, Randomized, Double-Blind Clinical Trial

著录项

相似文献

相关主题

期刊订阅